- Home
- PHVS vs VRDN Comparison
PHVS vs VRDN Comparison
Compare PHVS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- VRDN
- Stock Information
- Founded
- PHVS 2015
- VRDN 2006
- Country
- PHVS Switzerland
- VRDN United States
- Employees
- PHVS N/A
- VRDN N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- VRDN Medical Specialities
- Sector
- PHVS Health Care
- VRDN Health Care
- Exchange
- PHVS Nasdaq
- VRDN Nasdaq
- Market Cap
- PHVS 909.5M
- VRDN 1.0B
- IPO Year
- PHVS 2021
- VRDN N/A
- Fundamental
- Price
- PHVS $16.49
- VRDN $13.97
- Analyst Decision
- PHVS Strong Buy
- VRDN Strong Buy
- Analyst Count
- PHVS 5
- VRDN 12
- Target Price
- PHVS $39.20
- VRDN $38.50
- AVG Volume (30 Days)
- PHVS 59.6K
- VRDN 785.8K
- Earning Date
- PHVS 05-13-2025
- VRDN 05-06-2025
- Dividend Yield
- PHVS N/A
- VRDN N/A
- EPS Growth
- PHVS N/A
- VRDN N/A
- EPS
- PHVS N/A
- VRDN N/A
- Revenue
- PHVS N/A
- VRDN $302,000.00
- Revenue This Year
- PHVS N/A
- VRDN N/A
- Revenue Next Year
- PHVS N/A
- VRDN $21,976.14
- P/E Ratio
- PHVS N/A
- VRDN N/A
- Revenue Growth
- PHVS N/A
- VRDN 4.86
- 52 Week Low
- PHVS $11.51
- VRDN $9.90
- 52 Week High
- PHVS $25.50
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- PHVS 51.83
- VRDN 56.41
- Support Level
- PHVS $15.46
- VRDN $13.37
- Resistance Level
- PHVS $16.99
- VRDN $14.18
- Average True Range (ATR)
- PHVS 1.04
- VRDN 0.68
- MACD
- PHVS -0.08
- VRDN 0.13
- Stochastic Oscillator
- PHVS 71.48
- VRDN 75.40
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).